Encore Medical IPO Targets $15M to Fund US Cardiac Device Trials

TL;DR

**Encore Medical is a high-risk bet on future FDA approval for its PFO device, with current losses and fierce competition making this IPO a speculative play.**

AI Summary

Encore Medical, Inc. (EMI) is launching an initial public offering of 3,000,000 shares at an expected price of $5.00 per share, aiming to raise $15,000,000 before underwriting discounts of $1,200,000. The company, founded in 2017, specializes in transcatheter closure devices for cardiac defects, with over 35,000 successful implants outside the U.S. Its primary focus is on PFO closure devices for stroke prevention, targeting a potential annual U.S. market exceeding $1.5 billion based on 139,000 patients and an $11,000 average sales price. EMI has incurred net losses since inception and expects continued losses, relying on this IPO to finance its U.S. clinical trials for stroke and migraine indications. The company faces significant risks, including the inability to complete clinical trials, intense competition from giants like Abbott Laboratories and W. L. Gore & Associates, and the need for additional capital beyond this offering to achieve commercialization and avoid going concern issues. Regulatory approval in the U.S. is contingent on successful FDA clinical trials, estimated to take two years, followed by a PMA application.

Why It Matters

This S-1/A filing marks Encore Medical's attempt to tap public markets for critical funding, primarily to finance its U.S. clinical trials for PFO closure devices. For investors, it represents a high-risk, high-reward opportunity in the competitive structural heart device market, where established players like Abbott Laboratories and W. L. Gore & Associates dominate. Employees and customers could see significant growth if FDA approval is secured, expanding market access beyond the current 20 international countries. The broader medical device market will watch to see if EMI's 'proven design' with 35,000+ global implants can disrupt the U.S. landscape for stroke and migraine prevention.

Risk Assessment

Risk Level: high — The company explicitly states it has 'incurred net losses since inception' and 'expects to incur net losses for the foreseeable future,' indicating a lack of profitability. Furthermore, the entire U.S. market entry, which represents a potential $1.5 billion opportunity, is contingent on 'successful completion' of FDA clinical trials, estimated to take 'approximately two years,' with 'no assurance' of approval, creating significant regulatory and timeline uncertainty. The filing also highlights 'intense competition' from 'large, well-established medical device manufacturers' like Abbott Laboratories and W. L. Gore & Associates, which possess 'significantly greater financial, technical, manufacturing, marketing, sales, regulatory, distribution, and other resources.'

Analyst Insight

Investors should approach Encore Medical with extreme caution, recognizing the significant regulatory and financial hurdles. Consider a small, speculative position only if you have a high-risk tolerance and believe in the long-term potential of their PFO device to gain FDA approval and compete effectively against industry giants. Monitor clinical trial progress and FDA communications closely.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Executive Compensation

Key Numbers

• $15,000,000 — Total initial public offering price (Gross proceeds from selling 3,000,000 shares at $5.00 each)
• 3,000,000 — Shares of common stock offered (Number of shares being sold in the initial public offering)
• $5.00 — Expected initial public offering price per share (The anticipated price for each share of common stock)
• $1,200,000 — Underwriting discounts and commissions (8% of the total offering price, reducing net proceeds)
• $13,800,000 — Proceeds, before expenses, to Encore Medical, Inc. (Net proceeds after underwriting discounts)
• 450,000 — Additional shares for over-allotment option (Underwriters' option to purchase more shares within 45 days)
• 35,000 — Approximate number of patients implanted (Number of patients who have received Encore Medical's septal occlusion devices outside the U.S.)
• $1.5 billion — Potential annual U.S. market for PFO products for stroke prevention (Estimated market size based on 139,000 patients and an $11,000 average sales price)
• 2 years — Estimated time to complete FDA clinical trial (Projected duration for the U.S. clinical trial for PFO septal occlusion device for stroke)
• 8% — Underwriter's fee (Percentage of the amount raised paid to underwriters)

Key Players & Entities

• Encore Medical, Inc. (company) — Registrant and issuer of common stock
• Joseph A. Marino (person) — President and Chief Executive Officer of Encore Medical, Inc.
• Amy Bowler (person) — Legal counsel from Holland & Hart LLP
• William M. Mower (person) — Legal counsel from Maslon LLP
• Andrew M. Tataryn (person) — Legal counsel from Maslon LLP
• Abbott Laboratories (company) — Primary competitor for PFO devices
• W. L. Gore & Associates (company) — Primary competitor for PFO devices
• SEC (regulator) — Securities and Exchange Commission
• FDA (regulator) — U.S. Food and Drug Administration
• NYSE American Market (company) — Proposed stock exchange for EMI listing

FAQ

Risk Factors

• Going Concern and Need for Additional Capital [high — financial]: The company has incurred net losses since inception and expects continued losses. The current IPO aims to raise $15,000,000, but this may not be sufficient to fund U.S. clinical trials and achieve commercialization, raising substantial doubt about the company's ability to continue as a going concern.
• Clinical Trial and FDA Approval Uncertainty [high — regulatory]: Successful U.S. commercialization is contingent on completing FDA clinical trials, estimated to take two years, followed by a PMA application. Failure to complete these trials successfully or obtain regulatory approval would prevent market entry.
• Intense Competition [high — market]: Encore Medical faces significant competition from established players like Abbott Laboratories and W. L. Gore & Associates in the transcatheter closure device market. These competitors have greater financial resources and market presence.
• Dependence on Key Personnel and Technology [medium — operational]: The success of Encore Medical relies heavily on its specialized transcatheter closure devices and the expertise of its management and scientific teams. Any loss of key personnel or failure to advance its technology could severely impact the business.
• IPO Proceeds Insufficiency [high — financial]: While the IPO aims to raise $15,000,000, the company anticipates needing additional capital beyond this offering to fund its operations, clinical trials, and eventual commercialization. Failure to secure future funding could jeopardize its viability.

Industry Context

The transcatheter closure device market is highly competitive, with significant innovation and established players like Abbott and W. L. Gore. Encore Medical is targeting the PFO closure segment for stroke prevention, a substantial market opportunity estimated at over $1.5 billion annually in the U.S.

Regulatory Implications

Encore Medical's U.S. market entry is entirely dependent on successful completion of FDA clinical trials, estimated to take two years, followed by a rigorous PMA application process. Failure to navigate these regulatory hurdles will prevent commercialization.

What Investors Should Do

1. Evaluate the long-term viability of the company's clinical trial strategy and FDA approval timeline.
2. Assess the competitive landscape and Encore Medical's differentiation against established players.
3. Analyze the company's cash burn rate and future capital requirements beyond the IPO.

Glossary

Transcatheter Closure Devices

Medical devices delivered via a catheter through blood vessels to close abnormal openings in the heart, such as septal defects. (These are Encore Medical's core products, central to their business model and the purpose of the IPO.)

PFO

Patent Foramen Ovale, an opening between the two upper chambers of the heart that normally closes after birth. (Encore Medical is developing devices for PFO closure, specifically targeting stroke prevention, which is a key market opportunity.)

IPO

Initial Public Offering, the first time a company sells its stock to the public. (This S-1/A filing is for Encore Medical's IPO, aiming to raise capital for its operations and clinical trials.)

PMA

Premarket Approval, the FDA process of granting approval to market a medical device. (Encore Medical will need to obtain PMA approval after successful clinical trials to sell its devices in the U.S.)

Going Concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The filing indicates substantial doubt about Encore Medical's ability to continue as a going concern, highlighting financial risks.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial public offering, there is no prior public filing to compare key metrics against. The document outlines the company's financial position and operational plans from inception, highlighting historical losses and the need for capital.

Key Financial Figures

• $11,000 — nd at an assumed average sales price of $11,000 for each of our products, the potential
• $1.5 billion — oducts for stroke prevention may exceed $1.5 billion. Previous clinical experiences indica
• $1.235 billion — ing growth company if we have more than $1.235 billion in annual gross revenues as of the end
• $700 million — d of our fiscal year, we have more than $700 million in market value of our common stock hel
• $1.0 billion — nd fiscal quarter or we issue more than $1.0 billion of non-convertible debt over a three-ye

Filing Documents

• tm2525595-3_s1.htm (S-1/A) — 1816KB
• tm2525595d4_ex1-1.htm (EX-1.1) — 214KB
• tm2525595d4_ex3-2.htm (EX-3.2) — 13KB
• tm2525595d4_ex3-3.htm (EX-3.3) — 15KB
• tm2525595d4_ex3-4.htm (EX-3.4) — 45KB
• tm2525595d4_ex10-1.htm (EX-10.1) — 53KB
• tm2525595d4_ex10-2.htm (EX-10.2) — 133KB
• tm2525595d4_ex10-3.htm (EX-10.3) — 11KB
• tm2525595d4_ex10-4.htm (EX-10.4) — 368KB
• tm2525595d4_ex10-4a.htm (EX-10.4(A)) — 138KB
• tm2525595d4_ex10-4b.htm (EX-10.4(B)) — 20KB
• tm2525595d4_ex10-4c.htm (EX-10.4(C)) — 19KB
• tm2525595d4_ex10-6.htm (EX-10.6) — 41KB
• tm2525595d4_ex10-7.htm (EX-10.7) — 28KB
• tm2525595d4_ex10-8.htm (EX-10.8) — 24KB
• tm2525595d4_ex10-9.htm (EX-10.9) — 22KB
• tm2525595d4_ex23-1.htm (EX-23.1) — 4KB
• lg_boulay-4c.jpg (GRAPHIC) — 13KB
• lg_emi-4c.jpg (GRAPHIC) — 11KB
• lg_encoremedical-4c.jpg (GRAPHIC) — 13KB
• ph_pfoproduct01-4clr.jpg (GRAPHIC) — 11KB
• ph_pfoproduct02-4clr.jpg (GRAPHIC) — 35KB
• ph_pfoproduct03-4clr.jpg (GRAPHIC) — 22KB
• sg_boulaypllp-bw.jpg (GRAPHIC) — 8KB
• tm2525595d4_ex10-2img001.jpg (GRAPHIC) — 30KB
• tm2525595d4_ex10-2img002.jpg (GRAPHIC) — 90KB
• tm2525595d4_ex10-2img003.jpg (GRAPHIC) — 39KB
• tm2525595d4_ex10-2img004.jpg (GRAPHIC) — 60KB
• tm2525595d4_ex10-2img005.jpg (GRAPHIC) — 67KB
• tm2525595d4_ex10-4bimg01.jpg (GRAPHIC) — 17KB
• tm2525595d4_ex3-2img01.jpg (GRAPHIC) — 27KB
• tm2525595d4_ex3-2img02.jpg (GRAPHIC) — 11KB
• tm2525595d4_ex23-1img001.jpg (GRAPHIC) — 3KB
• tm2525595d4_ex23-1img002.jpg (GRAPHIC) — 8KB
• 0001104659-25-125214.txt ( ) — 3608KB

RISK FACTORS

RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 24

USE OF PROCEEDS

USE OF PROCEEDS 26 DIVIDEND POLICY 27 CAPITALIZATION 28 SERIES A PREFERRED STOCK CONVERSION 30

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 33

BUSINESS

BUSINESS 45 MANAGEMENT 55

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 61 PRINCIPAL SHAREHOLDERS 64

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 65 SHARES ELIGIBLE FOR FUTURE SALE 67 PLAN OF DISTRIBUTION 69 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCK 73 LEGAL MATTERS 74 EXPERTS 75 WHERE YOU CAN FIND MORE INFORMATION 76 Index to Financial Statements F-1 i TABLE OF CONTENTS Through and including [], 2025 (the 25 th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer's obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any related free writing prospectuses. Neither we nor any of the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or any sale of shares. Our business, financial condition, results of operations, and prospectus may have changed since that date. For investors outside of the United States: neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourself about, and observe any restrictions relating to, this offering of the sha

View Full Filing

View this S-1/A filing on SEC EDGAR